Try our beta test site

Clinical Trial of CNS-targeted HAART (CIT2)

This study has been completed.
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Ronald J Ellis, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00624195
First received: February 15, 2008
Last updated: March 21, 2014
Last verified: March 2014
Results First Received: December 9, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Condition: HIV Infections
Intervention: Drug: FDA Approved Antiretroviral Therapy (see list below)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
CNS-targeted

CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).

Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir

Non-CNS-targeted

Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen designed to suppress plasma Viral Load, but not to expected to have targeted CNS penetration.

Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir


Participant Flow:   Overall Study
    CNS-targeted   Non-CNS-targeted
STARTED   29   30 
COMPLETED   26   23 
NOT COMPLETED   3   7 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
CNS-targeted CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, underdosing).
Non-CNS-targeted Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen designed to suppress plasma Viral Load, but not to expected to have targeted CNS penetration.
Total Total of all reporting groups

Baseline Measures
   CNS-targeted   Non-CNS-targeted   Total 
Overall Participants Analyzed 
[Units: Participants]
 29   30   59 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   29   30   59 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 45.5  (8.8)   43.6  (11.1)   44.5  (9.9) 
Gender 
[Units: Participants]
     
Female   5   6   11 
Male   24   24   48 
Region of Enrollment 
[Units: Participants]
     
United States   29   30   59 


  Outcome Measures

1.  Primary:   Neuropsychological Performance Change   [ Time Frame: Baseline and 16 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Ron Ellis
Organization: UCSD
phone: 619-543-5079
e-mail: roellis@ucsd.edu


Publications of Results:
Other Publications:

Responsible Party: Ronald J Ellis, University of California, San Diego
ClinicalTrials.gov Identifier: NCT00624195     History of Changes
Other Study ID Numbers: 060154
R01MH058076-09A2 ( US NIH Grant/Contract Award Number )
Study First Received: February 15, 2008
Results First Received: December 9, 2013
Last Updated: March 21, 2014